Spyre Therapeutics (SYRE) Invested Capital (2015 - 2026)
Spyre Therapeutics posted quarterly Invested Capital of $721.1 million for Q1 2026, up 37.24% year-on-year from $525.4 million in Q1 2025, and down 2.3% on a QoQ basis from $738.1 million in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Invested Capital data on file, last reported at $721.1 million in Q1 2026.
- For the quarter ending Q1 2026, Invested Capital rose 37.24% year-over-year to $721.1 million; the trailing twelve-month figure through Mar 2026 stood at $721.1 million (up 37.24% YoY), and the FY2025 full-year result was $738.1 million, up 35.95% from the prior year.
- Invested Capital for Q1 2026 stood at $721.1 million, down from $738.1 million in the prior quarter.
- Across five years, Invested Capital topped out at $738.1 million in Q4 2025 and bottomed at -$237.9 million in Q3 2023.
- The 5-year median for Invested Capital is $185.4 million (2023), against an average of $270.3 million.
- The widest annual swing landed in 2023, when Invested Capital sank 452.15%; it then soared 977.07% in 2024.
- A 5-year view of Invested Capital shows it stood at $50.3 million in 2022, then jumped by 268.56% to $185.4 million in 2023, then surged by 192.81% to $542.9 million in 2024, then jumped by 35.95% to $738.1 million in 2025, then declined by 2.3% to $721.1 million in 2026.
- The last three Invested Capital figures came in at $721.1 million (Q1 2026), $738.1 million (Q4 2025), and $466.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 595,226.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | 721.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 721.07 Mn |
| Dec 31, 2025 | 738.06 Mn |
| Sep 30, 2025 | 466.12 Mn |
| Jun 30, 2025 | 515.67 Mn |
| Mar 31, 2025 | 525.42 Mn |
| Dec 31, 2024 | 542.88 Mn |
| Sep 30, 2024 | 352.13 Mn |
| Jun 30, 2024 | 377.03 Mn |
| Mar 31, 2024 | 154.86 Mn |
| Dec 31, 2023 | 185.41 Mn |
| Sep 30, 2023 | -237.89 Mn |
| Jun 30, 2023 | -42.99 Mn |
| Mar 31, 2023 | 33.65 Mn |
| Dec 31, 2022 | 50.31 Mn |
| Sep 30, 2022 | 67.56 Mn |
| Jun 30, 2022 | 84.16 Mn |
| Mar 31, 2022 | 61.66 Mn |
| Dec 31, 2021 | 83.94 Mn |
| Sep 30, 2021 | 102.08 Mn |
| Jun 30, 2021 | 119.02 Mn |
| Mar 31, 2021 | 123.76 Mn |
| Dec 31, 2020 | 139.83 Mn |
| Sep 30, 2020 | 136.27 Mn |
| Jun 30, 2020 | 152.26 Mn |
| Mar 31, 2020 | 42.81 Mn |
| Dec 31, 2019 | 60.08 Mn |
| Sep 30, 2019 | 79.80 Mn |
| Jun 30, 2019 | 99.62 Mn |
| Mar 31, 2019 | 116.29 Mn |
| Dec 31, 2018 | 67.43 Mn |
| Sep 30, 2018 | 63.68 Mn |
| Jun 30, 2018 | 73.45 Mn |
| Mar 31, 2018 | 43.92 Mn |
| Dec 31, 2017 | 50.34 Mn |
| Sep 30, 2017 | 55.51 Mn |
| Jun 30, 2017 | 62.60 Mn |
| Mar 31, 2017 | 57.18 Mn |
| Dec 31, 2016 | 62.97 Mn |
| Sep 30, 2016 | 68.20 Mn |
| Jun 30, 2016 | 73.92 Mn |
| Mar 31, 2016 | -26.61 Mn |
| Dec 31, 2015 | -22.21 Mn |